ATE498405T1 - Verwendung von botulinumtoxin für die verlängerte lokale desensibilisierung - Google Patents

Verwendung von botulinumtoxin für die verlängerte lokale desensibilisierung

Info

Publication number: ATE498405T1
Authority: AT; Austria
Prior art keywords: botulinum toxin; prolonged local; local desensitization; desensitization; skin
Prior art date: 2004-12-21

Application number

AT05850558T

Other languages

English (en)

Inventor

Roland Cherif-Cheikh

Original Assignee

Ipsen Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-21

Filing date

2005-12-21

Publication date

2011-03-15

2005-12-21 Application filed by Ipsen Pharma filed Critical Ipsen Pharma

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE498405T1 publication Critical patent/ATE498405T1/de

Links

108030001720 Bontoxilysin Proteins 0.000 title abstract 2
229940053031 botulinum toxin Drugs 0.000 title abstract 2
238000000586 desensitisation Methods 0.000 title 1
230000002035 prolonged effect Effects 0.000 title 1
239000003814 drug Substances 0.000 abstract 2
239000007924 injection Substances 0.000 abstract 2
238000002347 injection Methods 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000000122 growth hormone Substances 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000007888 toxin activity Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Anesthesiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

AT05850558T 2004-12-21 2005-12-21 Verwendung von botulinumtoxin für die verlängerte lokale desensibilisierung ATE498405T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0413650A FR2879462B1 (fr)	2004-12-21	2004-12-21	Utilisation de toxine botulique pour une insensibilisation locale prolongee
PCT/FR2005/003209 WO2006067332A1 (fr)	2004-12-21	2005-12-21	Utilisation de toxine botulique pour une insensibilisation locale prolongee

Publications (1)

Publication Number	Publication Date
ATE498405T1 true ATE498405T1 (de)	2011-03-15

Family

ID=34953956

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05850558T ATE498405T1 (de)	2004-12-21	2005-12-21	Verwendung von botulinumtoxin für die verlängerte lokale desensibilisierung

Country Status (7)

Country	Link
US (1)	US20090186052A1 (de)
EP (1)	EP1850863B1 (de)
AT (1)	ATE498405T1 (de)
CA (1)	CA2591608A1 (de)
DE (1)	DE602005026459D1 (de)
FR (1)	FR2879462B1 (de)
WO (1)	WO2006067332A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9211248B2 (en)	2004-03-03	2015-12-15	Revance Therapeutics, Inc.	Compositions and methods for topical application and transdermal delivery of botulinum toxins
US10792344B2 (en)	2006-06-29	2020-10-06	Merz Pharma Gmbh & Co. Kgaa	High frequency application of botulinum toxin therapy
AR061669A1 (es)	2006-06-29	2008-09-10	Merz Pharma Gmbh & Co Kgaa	Aplicacion de alta frecuencia de terapia con toxina botulinica
US8454975B1 (en) *	2010-01-11	2013-06-04	Elizabeth VanderVeer	Method for enhancing skin appearance
US9764010B2 (en) *	2012-08-24	2017-09-19	Allergan, Inc.	Method for treating premature ejaculation with a neurotoxin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH07157424A (ja) *	1993-12-03	1995-06-20	Lintec Corp	局所麻酔用ゲル製剤
GB9508204D0 (en) *	1995-04-21	1995-06-07	Speywood Lab Ltd	A novel agent able to modify peripheral afferent function
WO2000024419A1 (en) *	1998-10-27	2000-05-04	Mayo Foundation For Medical Education And Research	Methods for enhancing wound healing
ATE488529T1 (de) *	1999-07-28	2010-12-15	Genentech Inc	Zusammensetzungen und verfahren zur behandlung von tumoren
US20030180289A1 (en) *	1999-09-23	2003-09-25	Foster Keith Alan	Inhibition of secretion from non-neuronal cells
US7838008B2 (en) *	1999-12-07	2010-11-23	Allergan, Inc.	Methods for treating diverse cancers
US6464986B1 (en) *	2000-04-14	2002-10-15	Allegan Sales, Inc.	Method for treating pain by peripheral administration of a neurotoxin
US6306423B1 (en) *	2000-06-02	2001-10-23	Allergan Sales, Inc.	Neurotoxin implant
US20040170665A1 (en) *	2000-06-02	2004-09-02	Allergan, Inc.	Intravitreal botulinum toxin implant
US20040220100A1 (en) *	2000-07-21	2004-11-04	Essentia Biosystems, Inc.	Multi-component biological transport systems
US20040009180A1 (en) *	2002-07-11	2004-01-15	Allergan, Inc.	Transdermal botulinum toxin compositions
US6896666B2 (en) *	2002-11-08	2005-05-24	Kochamba Family Trust	Cutaneous injection delivery under suction
WO2004084839A2 (en) *	2003-03-24	2004-10-07	Cady Roger K	Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US7393537B2 (en) *	2003-04-25	2008-07-01	Allergan, Inc.	Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US7393538B2 (en) *	2003-04-25	2008-07-01	Ackerman Alan H	Clostridial toxin treatment for dermatillomania
US8734810B2 (en) *	2003-10-29	2014-05-27	Allergan, Inc.	Botulinum toxin treatments of neurological and neuropsychiatric disorders
GB0328060D0 (en) *	2003-12-04	2004-01-07	Sod Conseils Rech Applic	Botulinum toxin treatment
US7270287B2 (en) *	2004-01-06	2007-09-18	Allergan, Inc.	Botulinum toxin treatment for kinesia
US20050220821A1 (en) *	2004-03-31	2005-10-06	Allergan, Inc.	Pressure sore treatment
US20050220734A1 (en) *	2004-04-02	2005-10-06	Allergan, Inc.	Therapy for melanin related afflictions

2004
- 2004-12-21 FR FR0413650A patent/FR2879462B1/fr not_active Expired - Fee Related
2005
- 2005-12-21 AT AT05850558T patent/ATE498405T1/de not_active IP Right Cessation
- 2005-12-21 US US11/722,459 patent/US20090186052A1/en not_active Abandoned
- 2005-12-21 EP EP05850558A patent/EP1850863B1/de not_active Expired - Lifetime
- 2005-12-21 WO PCT/FR2005/003209 patent/WO2006067332A1/fr not_active Ceased
- 2005-12-21 DE DE602005026459T patent/DE602005026459D1/de not_active Expired - Lifetime
- 2005-12-21 CA CA002591608A patent/CA2591608A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
DE602005026459D1 (de)	2011-03-31
WO2006067332A1 (fr)	2006-06-29
EP1850863A1 (de)	2007-11-07
CA2591608A1 (fr)	2006-06-29
EP1850863B1 (de)	2011-02-16
FR2879462B1 (fr)	2008-12-26
FR2879462A1 (fr)	2006-06-23
US20090186052A1 (en)	2009-07-23

Similar Documents

Publication	Publication Date	Title
DE602006014934D1 (de)	2010-07-29	Verwaltung ausstehender arzneimittelbestellungen
BRPI0509806A (pt)	2007-09-18	sistema de injeção em múltiplos locais
ATE439123T1 (de)	2009-08-15	Verwendung von emulsionen zur intra- und periocularen injection
AR099078A2 (es)	2016-06-29	Un medicamento que comprende acetato de glatiramer
WO2010118327A3 (en)	2011-01-13	Targeted health care content delivery system
EA200801575A1 (ru)	2008-12-30	Трансдермальная доставка мептазинола
AR073717A1 (es)	2010-11-24	Anticuerpos anti-notch2 de murino y humano, y metodos de uso
WO2012048830A3 (en)	2012-06-21	Time block manipulation for insulin infusion delivery
MX2016008138A (es)	2016-09-16	Sistema para el suministro transdermico de ingredientes activos.
ATE444076T1 (de)	2009-10-15	Verwendung von botulintoxin zur linderung von hodenschmerzen
ATE419842T1 (de)	2009-01-15	Abgabevehikel mit nanoteilchen
EA200601777A1 (ru)	2007-02-27	Новое применение пептидных соединений для лечения боли при болезненной диабетической нейропатии
ATE353655T1 (de)	2007-03-15	Myo-inositol hexaphosphat zur topischen verwendung
WO2014017971A3 (en)	2014-03-20	Improved clinical effect of pharmaceutical products using communication tool integrated with compound of several pharmaceutical products
ATE420099T1 (de)	2009-01-15	Medikament zur wachstumsinhibierung von tumoren
ATE498405T1 (de)	2011-03-15	Verwendung von botulinumtoxin für die verlängerte lokale desensibilisierung
TW200630128A (en)	2006-09-01	Active ingredient-containing silicone elastomers
ATE553189T1 (de)	2012-04-15	Immunokinasen
WO2006039343A3 (en)	2007-01-04	Emmprin antagonists and uses thereof
AR048811A1 (es)	2006-05-31	Uso de toxina botulinica en la preparacion de un medicamento para evitar el crecimiento del vello
ATE458819T1 (de)	2010-03-15	Konjugat mit p21-protein zur krebsbehandlung
DE60035504D1 (de)	2007-08-23	Verfahren für die verabreichung von heilmitteln mittels einer dextrinlösung
BR112022005067A2 (pt)	2022-09-06	Fibroblastos vasculogênicos
TR201106571A2 (tr)	2013-01-21	İnsulin parçalayan enzimin (IDE) aktivitesini düzenleyen bir molekül.
MX2022013237A (es)	2022-11-14	Maltodextrinas entrelazadas para el suministro oral de activos biologicos.

Legal Events

Date	Code	Title	Description
2011-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties